Veraxa Biotech Holding AG (NASDAQ:VRXA) Sees Significant Decrease in Short Interest

Veraxa Biotech Holding AG (NASDAQ:VRXA) was the recipient of a large decrease in short interest during the month of October. As of October 15th, there was short interest totaling 107,383 shares, a decrease of 54.3% from the September 30th total of 235,019 shares. Based on an average trading volume of 421,031 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.3% of the shares of the stock are short sold.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded Veraxa Biotech from a “sell” rating to a “hold” rating in a report on Monday, August 31st.

Insider Transactions at Veraxa Biotech

In other news, Director Oliver Baumann acquired 50,000 shares of the firm’s stock in a transaction on Thursday, August 27th. The shares were purchased at an average cost of $1.50 per share, for a total transaction of $75,000.00. Following the transaction, the director owned 5,773,618 shares of the company’s stock, valued at approximately $8,660,427. This represents a 0.87% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Christoph Samuel Ziegler acquired 30,000 shares of the stock in a transaction that occurred on Tuesday, October 20th. The stock was purchased at an average price of $1.09 per share, with a total value of $32,700.00. Following the completion of the transaction, the director owned 37,932 shares of the company’s stock, valued at approximately $41,345.88. This trade represents a 378.21% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders acquired 95,000 shares of company stock valued at $125,333.

Veraxa Biotech Stock Performance

Shares of VRXA stock opened at $1.13 on Friday. Veraxa Biotech has a 12 month low of $0.95 and a 12 month high of $27.36. The stock has a fifty day simple moving average of $1.29.

About Veraxa Biotech

VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation.